CHAL 12 - FTC scrutiny of patent settlements in Hatch-Waxman cases

被引：0

作者：

McKithen, Marc ^{[1
]}

机构：

[1] Milbank Tweed Hadley & McCLoy, New York, NY 10005 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 237卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

12-CHAL

引用

收藏

页码：953 / 953

页数：1

相关论文

共 16 条

[11] CHAL 11 - Patents, competition, antitrust and generic drugs: Resolving Hatch-Waxman Act issues [J].

Drake, Kirby .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 :948-948

[12] Patent term extensions for human drugs under the US Hatch-Waxman Act [J].

Boone, Jeffrey S. .

JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2009, 4 (09) :658-664

[13] Continuing Abuse of the Hatch-Waxman Act by Pharmaceutical Patent Holders and the Failure of the 2003 Amendments [J].

Avery, Matthew .

HASTINGS LAW JOURNAL, 2008, 60 (01) :171-+

[14] Hatch-Waxman 101: A practical guide on the regulatory impact of exclusivity, patents, and patent litigation on generic drug development and approval [J].

Toufanian, Maryll .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251

[15] Expanding the scope of the Hatch-Waxman Act's patent carve-out exception to the identical drug labeling requirement: Closing the patent litigation loophole [J].

Dohm, Julie .

UNIVERSITY OF PENNSYLVANIA LAW REVIEW, 2007, 156 (01) :151-196

[16] GENERICS AND BIOSIMILARS: MAPPING THE BIOSIMILARS REGULATORY APPROVAL PATHWAY AGAINST THE HATCH-WAXMAN ACT AND PROJECTING FUTURE EFFECTS ON THE BIOLOGICS MARKET AND PATENT PROTECTION [J].

Montgomery, Michael S. .

UNIVERSITY OF PITTSBURGH LAW REVIEW, 2014, 75 (03) :387-408